Geneseeq, Author at Geneseeq Technology Inc. | A Precision Oncology Company

April 13, 2023

Geneseeq co-publish with UHN on using ctDNA as a prognostic biomarker for immunotherapy

0 Comments3 Minutes

April 11, 2023

Geneseeq to Present 13 Posters at AACR 2023

0 Comments3 Minutes

March 9, 2023

Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer

0 Comments2 Minutes

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

0 Comments2 Minutes

November 15, 2022

Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM

0 Comments4 Minutes

November 3, 2022

Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy

0 Comments3 Minutes

October 18, 2022

Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy

0 Comments3 Minutes

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

0 Comments4 Minutes

September 7, 2022

Geneseeq to present five posters at European Society for Medical Oncology 2022

0 Comments6 Minutes

August 3, 2022

GENESEEQ AND COLLABORATORS SHARE NEW FINDINGS AT WORLD CONFERENCE ON LUNG CANCER 2022

0 Comments10 Minutes